Achmea Investment Management B.V. Bei Gene, Ltd. Transaction History

Achmea Investment Management B.V.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$123.9 - $195.41 $685,167 - $1.08 Million	-5,530 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$121.84 - $173.19 $358,087 - $509,005	2,939 Added 113.43%	5,530 $681,000
Q4 2019 Feb 10, 2020	BUY	$115.78 - $208.34 $299,985 - $539,808	2,591 New	2,591 $429,000
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $482,922 - $593,753	-4,004 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$113.99 - $146.86 $456,415 - $588,027	4,004 New	4,004 $496,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Achmea Investment Management B.V., based on Form 13F filings with the SEC.

Stay updated on Achmea Investment Management B.V. with notifications on news.